Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Endocyte Inc (ECYT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 181,944
  • Shares Outstanding, K 47,880
  • Annual Sales, $ 70 K
  • Annual Income, $ -43,890 K
  • 36-Month Beta 2.20
  • Price/Sales 2,305.34
  • Price/Cash Flow N/A
  • Price/Book 1.91

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.68 +3.26%
on 01/16/18
4.63 -17.93%
on 01/03/18
-0.61 (-13.83%)
since 12/15/17
3-Month
3.68 +3.26%
on 01/16/18
5.96 -36.24%
on 12/04/17
-0.50 (-11.73%)
since 10/16/17
52-Week
1.17 +224.79%
on 08/21/17
6.55 -41.98%
on 10/03/17
+1.23 (+47.86%)
since 01/13/17

Most Recent Stories

More News
Stock Review for Biotech's Investors -- Editas Medicine, Illumina, Tesaro, and Endocyte

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on EDIT, ILMN, TSRO, and ECYT which can be accessed for free by signing up to www.wallstequities.com/registration....

ILMN : 243.25 (+0.76%)
ECYT : 3.84 (+1.05%)
EDIT : 31.33 (+4.36%)
TSRO : 64.53 (-1.51%)
Options Traders Expect Huge Moves in Endocyte (ECYT) Stock

Investors in Endocyte (ECYT) need to pay close attention to the stock based on moves in the options market lately.

ECYT : 3.84 (+1.05%)
Endocyte Added to NASDAQ Biotechnology Index

Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that it has been selected for addition to the NASDAQ Biotechnology...

ECYT : 3.84 (+1.05%)
Options Traders Expect Huge Moves in Endocyte (ECYT) Stock

Surging implied volatility makes Endocyte (ECYT) stock lucrative to the option traders.

ECYT : 3.84 (+1.05%)
Analysis: Positioning to Benefit within FireEye, CSRA, Concho Resources, Trevena, Five Prime Therapeutics, and Endocyte -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of FireEye, Inc. (NASDAQ:FEYE),...

CSRA : 31.90 (-0.13%)
TRVN : 1.75 (+1.74%)
FPRX : 20.91 (+1.80%)
ECYT : 3.84 (+1.05%)
FEYE : 15.06 (+0.20%)
CXO : 156.83 (+0.07%)
Endocyte to Present at the Jefferies 2017 London Healthcare Conference

Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company's management team will present at the Jefferies...

ECYT : 3.84 (+1.05%)
Cancer Immunotherapy Technology Projected to Create Further Growth

According to data provided by Allied Market Research, the global cancer immunotherapy market is expected to grow to $117.14 billion by 2022, growing at a CAGR of 14.5 percent from the time period of 2016...

CLDX : 2.71 (+0.74%)
ARQL : 1.75 (-4.37%)
RGBP : 0.0483 (-2.23%)
RGBPP : 0.0451 (-13.27%)
ECYT : 3.84 (+1.05%)
CASI : 3.66 (-3.43%)
Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss

Endocyte (ECYT) posted narrower-than-expected loss in the third quarter of 2017. The company will focus on the development of PSMA-617 that it licensed in the same quarter.

AGEN : 3.90 (+2.90%)
LGND : 146.40 (+0.01%)
ECYT : 3.84 (+1.05%)
ADAP : 8.20 (+9.19%)
Endocyte Reports Third Quarter Financial Results

- Plans to Initiate Phase 3 Registration for Lu-PSMA-617 Accelerated by Radiomedix Agreement to Transfer Active U.S. Investigational New Drug Application (IND) to Endocyte -

ECYT : 3.84 (+1.05%)
Endocyte, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 6, 2017 / Endocyte, Inc. (NASDAQ: ECYT) will be discussing their earnings results in their Q3 Earnings Call to be held on November 6, 2017 at 4:30 PM Eastern Time.

ECYT : 3.84 (+1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators are in flux.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Endocyte, Inc. is a biopharmaceutical company engaged in the development of therapies for the treatment of cancer and inflammatory diseases. The Company creates novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. Endocyte, Inc. is based...

See More

Key Turning Points

2nd Resistance Point 4.31
1st Resistance Point 4.05
Last Price 3.84
1st Support Level 3.61
2nd Support Level 3.43

See More

52-Week High 6.55
Fibonacci 61.8% 4.49
Fibonacci 50% 3.86
Last Price 3.84
Fibonacci 38.2% 3.23
52-Week Low 1.17

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.